These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38996737)

  • 1. Comparative analysis of quantitative susceptibility mapping in preclinical dementia detection.
    Suresh Paul J; T AR; Raghavan S; Kesavadas C
    Eur J Radiol; 2024 Sep; 178():111598. PubMed ID: 38996737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI-derived brain iron, grey matter volume, and risk of dementia and Parkinson's disease: Observational and genetic analysis in the UK Biobank cohort.
    Casanova F; Tian Q; Williamson DS; Qian Y; Zweibaum D; Ding J; Atkins JL; Melzer D; Ferrucci L; Pilling LC
    Neurobiol Dis; 2024 Jul; 197():106539. PubMed ID: 38789058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping.
    Bilgic B; Pfefferbaum A; Rohlfing T; Sullivan EV; Adalsteinsson E
    Neuroimage; 2012 Feb; 59(3):2625-35. PubMed ID: 21925274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Study of the Changes in Cerebral Blood Flow and Iron Deposition During Progression of Alzheimer's Disease.
    Li D; Liu Y; Zeng X; Xiong Z; Yao Y; Liang D; Qu H; Xiang H; Yang Z; Nie L; Wu PY; Wang R
    J Alzheimers Dis; 2020; 78(1):439-452. PubMed ID: 32986675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of quantitative susceptibility mapping methods for iron-sensitive susceptibility imaging at 7T: An evaluation in healthy subjects and patients with Huntington's disease.
    Yao J; Morrison MA; Jakary A; Avadiappan S; Chen Y; Luitjens J; Glueck J; Driscoll T; Geschwind MD; Nelson AB; Villanueva-Meyer JE; Hess CP; Lupo JM
    Neuroimage; 2023 Jan; 265():119788. PubMed ID: 36476567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron quantification in basal ganglia using quantitative susceptibility mapping in a patient with ALS: a case report and literature review.
    Ghaderi S; Batouli SAH; Mohammadi S; Fatehi F
    Front Neurosci; 2023; 17():1229082. PubMed ID: 37877011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls - A hybrid PET/MRI study.
    Tiepolt S; Rullmann M; Jochimsen TH; Gertz HJ; Schroeter ML; Patt M; Sabri O; Barthel H
    Eur J Radiol; 2020 Oct; 131():109243. PubMed ID: 32916411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of quantitative susceptibility mapping methods on evaluating radiation-induced cerebral microbleeds and basal ganglia at 3T and 7T.
    Chen Y; Genc O; Poynton CB; Banerjee S; Hess CP; Lupo JM
    NMR Biomed; 2022 May; 35(5):e4666. PubMed ID: 35075701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations.
    Uchida Y; Kan H; Sakurai K; Oishi K; Matsukawa N
    Front Neurosci; 2022; 16():938092. PubMed ID: 35992906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer's disease.
    Yang A; Du L; Gao W; Liu B; Chen Y; Wang Y; Liu X; Lv K; Zhang W; Xia H; Wu K; Ma G
    Quant Imaging Med Surg; 2022 Sep; 12(9):4570-4586. PubMed ID: 36060596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early differentiation of neurodegenerative diseases using the novel QSM technique: what is the biomarker of each disorder?
    Nikparast F; Ganji Z; Zare H
    BMC Neurosci; 2022 Jul; 23(1):48. PubMed ID: 35902793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Thomas GEC; Hannaway N; Zarkali A; Shmueli K; Weil RS
    Mov Disord; 2024 Mar; 39(3):546-559. PubMed ID: 38173297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases.
    Ravanfar P; Loi SM; Syeda WT; Van Rheenen TE; Bush AI; Desmond P; Cropley VL; Lane DJR; Opazo CM; Moffat BA; Velakoulis D; Pantelis C
    Front Neurosci; 2021; 15():618435. PubMed ID: 33679303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron quantification in basal ganglia: quantitative susceptibility mapping as a potential biomarker for Alzheimer's disease - a systematic review and meta-analysis.
    Ghaderi S; Mohammadi S; Nezhad NJ; Karami S; Sayehmiri F
    Front Neurosci; 2024; 18():1338891. PubMed ID: 38469572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: A 3T and 7T MRI study.
    Alushaj E; Handfield-Jones N; Kuurstra A; Morava A; Menon RS; Owen AM; Sharma M; Khan AR; MacDonald PA
    Neuroimage Clin; 2024; 41():103577. PubMed ID: 38377722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy.
    Singh NA; Arani A; Graff-Radford J; Senjem ML; Martin PR; Machulda MM; Schwarz CG; Shu Y; Cogswell PM; Knopman DS; Petersen RC; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
    Neuroimage Clin; 2022; 36():103161. PubMed ID: 36029670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical utility of QSM: disease diagnosis, medical management, and surgical planning.
    Eskreis-Winkler S; Zhang Y; Zhang J; Liu Z; Dimov A; Gupta A; Wang Y
    NMR Biomed; 2017 Apr; 30(4):. PubMed ID: 27906525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of iron deposition in brain basal ganglia of patients with Parkinson's disease using quantitative susceptibility mapping.
    Shahmaei V; Faeghi F; Mohammdbeigi A; Hashemi H; Ashrafi F
    Eur J Radiol Open; 2019; 6():169-174. PubMed ID: 31065578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease.
    Chen Q; Boeve BF; Forghanian-Arani A; Senjem ML; Jack CR; Przybelski SA; Lesnick TG; Kremers WK; Fields JA; Schwarz CG; Gunter JL; Trzasko JD; Graff-Radford J; Savica R; Knopman DS; Dickson DW; Ferman TJ; Graff-Radford N; Petersen RC; Kantarci K
    J Neuroimaging; 2021 Sep; 31(5):1020-1027. PubMed ID: 34033185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.